Drug Trial Radar · NCT01422876
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Last checked: Nov 19, 2026Latest source record: Apr 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,405
Actual
Start
Aug 2011
Primary completion
Sep 2013
Study completion Sep 2013
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Aug 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.
Conditions
- Diabetes Mellitus, Type 2
Interventions
high dose FDCDrug
once daily
BI 10773 high doseDrug
once daily
high dose FDC placeboDrug
once daily
low dose FDC placeboDrug
once daily
high dose FDC placeboDrug
once daily
high dose FDC placeboDrug
once daily
low dose FDC placeboDrug
once daily
low dose FDC placeboDrug
once daily
high dose BI 10773 placeboDrug
once daily
low dose FDCDrug
once daily
high dose FDC placeboDrug
once daily
BI 10773 low doseDrug
low dose once daily
high dose BI 10773 placeboDrug
once daily
high dose BI 10773 placeboDrug
once daily
linagliptinDrug
once daily
low dose FDC placeboDrug
once daily
linagliptin placeboDrug
once daily
BI 10773 low dose placeboDrug
once daily
linagliptin placeboDrug
once daily
low dose BI 10773 placeboDrug
once daily
linagliptin placeboDrug
once daily
high dose BI 10773 placeboDrug
once daily
BI 10773 low dose placeboDrug
once daily
low dose BI 10773 placeboDrug
once daily
linagliptin placeboDrug
once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background PatientsTime frame: Baseline and 24 weeks
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive PatientsTime frame: Baseline and 24 weeks
Locations
211 sites in 22 countries. Site status is shown where the registry gives one.
1275.1.01103 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1275.1.01107 Boehringer Ingelheim Investigational Site
Foley, Alabama
1275.1.01043 Boehringer Ingelheim Investigational Site
Mobile, Alabama
1275.1.01066 Boehringer Ingelheim Investigational Site
Mobile, Alabama
1275.1.01047 Boehringer Ingelheim Investigational Site
Pell City, Alabama
1275.1.01089 Boehringer Ingelheim Investigational Site
Mesa, Arizona
1275.1.01064 Boehringer Ingelheim Investigational Site
Tempe, Arizona
1275.1.01028 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1275.1.01086 Boehringer Ingelheim Investigational Site
Cerritos, California
1275.1.01067 Boehringer Ingelheim Investigational Site
Chula Vista, California
1275.1.01109 Boehringer Ingelheim Investigational Site
Encino, California
1275.1.01012 Boehringer Ingelheim Investigational Site
Fresno, California
1275.1.01050 Boehringer Ingelheim Investigational Site
Harbor City, California
1275.1.01056 Boehringer Ingelheim Investigational Site
Huntington Park, California
1275.1.01021 Boehringer Ingelheim Investigational Site
Long Beach, California
1275.1.01024 Boehringer Ingelheim Investigational Site
Los Angeles, California
1275.1.01112 Boehringer Ingelheim Investigational Site
Los Angeles, California
1275.1.01083 Boehringer Ingelheim Investigational Site
Oceanside, California
1275.1.01071 Boehringer Ingelheim Investigational Site
San Dimas, California
1275.1.01044 Boehringer Ingelheim Investigational Site
Tustin, California
1275.1.01078 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado
1275.1.01124 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado
1275.1.01010 Boehringer Ingelheim Investigational Site
Denver, Colorado
1275.1.01048 Boehringer Ingelheim Investigational Site
Denver, Colorado
1275.1.01073 Boehringer Ingelheim Investigational Site
Gainesville, Florida
1275.1.01063 Boehringer Ingelheim Investigational Site
Hialeah, Florida
1275.1.01077 Boehringer Ingelheim Investigational Site
Hialeah, Florida
1275.1.01090 Boehringer Ingelheim Investigational Site
Inverness, Florida
1275.1.01054 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1275.1.01092 Boehringer Ingelheim Investigational Site
Maitland, Florida
1275.1.01065 Boehringer Ingelheim Investigational Site
Miami, Florida
1275.1.01110 Boehringer Ingelheim Investigational Site
Miami, Florida
1275.1.01040 Boehringer Ingelheim Investigational Site
Miami Beach, Florida
1275.1.01025 Boehringer Ingelheim Investigational Site
Miami Lakes, Florida
1275.1.01094 Boehringer Ingelheim Investigational Site
Orlando, Florida
1275.1.01068 Boehringer Ingelheim Investigational Site
Ormond Beach, Florida
1275.1.01051 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida
1275.1.01079 Boehringer Ingelheim Investigational Site
Port Orange, Florida
1275.1.01117 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
1275.1.01039 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
Showing 40 of 211 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.